Precision Metabolic Rewiring for High-Efficiency Amino Acid and Fine Chemical Production. Corynebacterium glutamicum is the cornerstone of the global amino acid industry and a vital host for synthetic biology. To move beyond single-gene edits toward systemic cellular optimization, CD Biosynsis provides professional C. glutamicum Multiplex Genome Engineering Services. Utilizing advanced CRISPR-Cas9 toolkits and Dual-In/Out strategies, we enable the simultaneous deactivation of multiple competitive pathways and the construction of robust industrial chassis. Whether your goal is thermal tolerance, substrate redirection, or high-titer amino acid synthesis, our platform delivers engineered strains ready for large-scale fermentation.
Get a Technical QuoteOur platform transforms C. glutamicum into a high-performance microbial cell factory through strategic genomic interventions. We focus on systemic metabolic rewiring to eliminate side-reactions and maximize product accumulation.
| Service Tier | Technical Strategy | Primary Application | Standard Deliverables |
|---|---|---|---|
| Industrial Tolerance | Dual-In/Out & ALE | Thermal (55°C) & pH stress tolerance | Validated robust strains + Sequencing data |
| Substrate Rewiring | CRISPR/Cas9 Multi-gene Deletion | Redirection of carbon flux (PTS-deficient) | Substrate-optimized strains + Yield analysis |
| Amino Acid Synthesis | HTP Metabolic Branch Knockout | L-threonine & Branched-chain amino acids | High-yield production strains + Titer reports |
| Chassis Streamlining | Large-fragment IS Deletion | Minimizing metabolic drag & off-targets | Optimized "Clean" chassis (e.g., CR100) |
1. Locus Evaluation & Modeling
2. Editing Strategy Selection
3. Genome Execution
4. Phenotypic Validation
Analyzing the metabolic network to identify high-impact knockout targets and competitive bypasses.
Formal project proposal and Mutual NDA signing.
Choosing between CRISPR-Cas9 for high-speed multiplexing or Dual-In/Out for complex iterations.
Design of high-specificity gRNAs to avoid off-target effects.
Simultaneous transformation and selection of multiple gene edits, including scarless deletions.
Pathway integration and metabolic network reconstruction.
Evaluating performance under industrial stress (heat, pH) or specific substrate constraints.
Final genetic verification via Sanger/WGS and characterization of titer performance.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. These studies demonstrate the power of multiplex engineering in industrial chassis development.
Industrial fermentation generates significant heat, hindering strain performance. Utilizing a Dual-In/Out strategy, research has optimized a platform for rapid multiplex editing. By knocking out stress-response regulators and performing directed evolution, industrial strains have been successfully evolved to maintain metabolic activity at temperatures up to 55°C, overcoming the limitations of traditional screening.
(Reference: Lobanova et al., 2022)
Redirecting carbon flux from growth to synthesis is critical. Using CRISPR/Cas9-assisted engineering on streamlined chassis (e.g., CR100), technical benchmarks achieved the simultaneous deletion of pts (sugar transport) and iolR (regulatory inhibitor) genes. This creates a metabolic state where the strain bypasses standard glucose utilization to focus entirely on high-efficiency synthesis of shikimate.
(Reference: Ou et al., 2025)
Maximizing amino acids like L-threonine requires the elimination of multiple competing branches. By constructing a CRISPR/Cas9-assisted genomic editing system, research has demonstrated the ability to rapidly knock out multiple genes encoding competitive enzymes. This high-throughput approach shuts down side-pathways, channeling resources into the target synthesis and establishing a model for industrial amino acid optimization.
(Reference: Liu et al., 2021)
Ready to design your C. glutamicum engineering strategy?
Contact Us1. How many genes can you knock out in a single round for C. glutamicum?
Utilizing our optimized CRISPR-Cas9 platform, we can typically target and deactivate 3 to 4 genes simultaneously in one round of engineering, depending on the host's fitness.
2. Can you perform edits in my proprietary industrial strain?
Yes. We have extensive experience adapting our toolkits to diverse C. glutamicum backgrounds, including polyploid or highly modified proprietary industrial strains.
3. What is the benefit of the Dual-In/Out strategy over standard CRISPR?
The Dual-In/Out strategy is exceptionally robust for iterative edits and large-fragment replacements. It allows for the insertion of heavy metabolic pathways with minimal genomic instability, ideal for long-term chassis development.
4. How do you verify the stability of the edits?
We conduct long-term genetic stability tests (e.g., 50–100 generations) and provide Whole Genome Sequencing (WGS) data to ensure no unwanted mutations or reversals have occurred.
5. Is the resulting strain considered "clean" for food-grade production?
Absolutely. We specialize in marker-free and scarless editing, ensuring the final strain contains no antibiotic resistance markers, meeting GRAS and food-grade safety standards.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.